LeonaBio, Inc. (LONA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LeonaBio, Inc. (LONA) has a cash flow conversion efficiency ratio of -0.424x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.90 Million) by net assets ($49.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LONA market cap for the company's overall valuation and market capitalisation.
LeonaBio, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
LeonaBio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LeonaBio, Inc. ranked by their cash flow conversion efficiency. See LeonaBio, Inc. debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anam Electroni
KO:008700
|
-0.077x |
|
Dawonsys Co.Ltd
KQ:068240
|
0.103x |
|
Gamma Nu Inc
KQ:192410
|
-0.167x |
|
Atinum Investment Co. Ltd
KQ:021080
|
0.098x |
|
Nature Holdings Co. Ltd.
KQ:298540
|
0.027x |
|
Aminologics Co.Ltd
KQ:074430
|
0.081x |
|
Alterity Therapeutics Limited
F:PBN
|
-0.093x |
|
Futebol Clube do Porto - Futebol S.A.D.
LS:FCP
|
-0.266x |
Annual Cash Flow Conversion Efficiency for LeonaBio, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of LeonaBio, Inc. from 2018 to 2025. View LONA live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.79 Million | $-45.73 Million | -1.646x | +24.06% |
| 2024-12-31 | $44.84 Million | $-97.17 Million | -2.167x | -180.01% |
| 2023-12-31 | $130.19 Million | $-100.75 Million | -0.774x | -151.11% |
| 2022-12-31 | $235.14 Million | $-72.47 Million | -0.308x | -129.61% |
| 2021-12-31 | $321.08 Million | $-43.10 Million | -0.134x | -52.68% |
| 2020-12-31 | $274.28 Million | $-24.11 Million | -0.088x | -146.70% |
| 2019-12-31 | $-19.72 Million | $-3.71 Million | 0.188x | -37.48% |
| 2018-12-31 | $-14.89 Million | $-4.48 Million | 0.301x | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more